Crizotinib as a first line treatment for ALK+ patients

We are pleased that crizotinib (xalkori) has been approved by NICE for use with a sub-group of people affected by lung cancer. It had previously been approved for use in Scotland by the Scottish Medicine Consorium (SMC). This is a new treatment for a small group of patients with ALK+ tumours. To work out if a targeted therapy may work for you your cancer doctor will carry out a test of your tumour tissue.

Crizotinib is now available as a first line treatment for those who are ALK+. ALK is a protein which encourages cancer cells to grow, divide and spread. It is found in approximately 3- 5% of those with non-small cell lung cancer. Previously those who were ALK+ had to undergo chemotherapy before a targeted therapy was provided.

We welcome NICE’s decision to approve this medicine which has been judged clinically and cost effective following the manufacturer, Pfizer’s, decision to offer a discount scheme to make the drug available to patients via the NHS.

More information on targeted therapies is available in our booklet. You can download it from our website roycastle.org/how-we-help/l...

Or get more information by calling our nurse led Freephone helpline on 0800 358 7200.

1 Reply

oldestnewest
  • That is really good news for people who are just being diagnosed as ALK positive. A step in the right direction. I am really pleased that it has been approved as a first line treatment. It has been a first line treatment in the US for at least the last 3 years. 😀

You may also like...